StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)

Form 8-K Product Sales Detail by Product and Geographic Region

QuarterlyAnnual
Latest, Q4 2022
-61.0%
Period ended Dec 31, 2022
Change on a year earlier
-1.0 pts
-60.0% in Q4 2021
History
18 quarters
Since Q3 2018
Sources
18
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q4 2022Dec 31, 2022-61.0%-1.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022-11.0%+40.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 2022-17.0%+53.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-13.0%+68.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021-60.0%-2.0 ptsForm 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021-51.0%+13.0 ptsForm 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 2021-70.0%-36.0 ptsForm 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-81.0%-39.0 ptsForm 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 2020-58.0%+18.0 ptsForm 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 2020-64.0%+9.0 ptsForm 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 2020-34.0%+37.0 ptsForm 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 2020-42.0%+15.0 ptsForm 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗
Q4 2019Dec 31, 2019-76.0%-84.0 ptsForm 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
Q3 2019Sep 30, 2019-73.0%-62.0 ptsForm 8-K (amgn-2019930xq3exhibit.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 2019-71.0%–Form 8-K (amgn-2019630xq2exhibit991f.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 2019-57.0%–Form 8-K (amgn-2019331xq1exhibit991f.htm, filed 2019-04-30) ↗

Cite this data

StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%), quarterly Q3 2018–Q4 2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_sensipar_yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.